Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders | |
Xu, Heng2; Lu, Hongfu1; Xu, Zhongmiao1; Luan, Linbo1; Li, Chengyong1; Xu, Yan1; Dong, Kelly1; Zhang, Jinqiang1; Li, Xiong1; Li, Yvonne1 | |
刊名 | ACS medicinal chemistry letters |
2016-04-14 | |
卷号 | 7期号:4页码:397-402 |
ISSN号 | 1948-5875 |
DOI | 10.1021/acsmedchemlett.5b00489 |
文献子类 | Article |
英文摘要 | Structure-activity relationship exploration of the historical biarylurea series led to the identification of novel CNS penetrant CXCR2 antagonists with nanomolar potency, favorable PK profile, and good developability potentials. More importantly, the key compound 22 showed efficacy in a cuprizone-induced demyelination model with twice daily oral administration, thereby supporting CXCR2 to be a potential therapeutic target for the treatment of demyelinating diseases such as multiple sclerosis. |
语种 | 英语 |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/266595] |
专题 | 中国科学院上海药物研究所 |
作者单位 | 1.Research and Development, GlaxoSmithKline , No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, P. R. China 2.State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences , 1 Xiannongtan Street, Beijing 100050, P. R. China; |
推荐引用方式 GB/T 7714 | Xu, Heng,Lu, Hongfu,Xu, Zhongmiao,et al. Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders[J]. ACS medicinal chemistry letters,2016,7(4):397-402. |
APA | Xu, Heng.,Lu, Hongfu.,Xu, Zhongmiao.,Luan, Linbo.,Li, Chengyong.,...&Lin, Xichen.(2016).Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.ACS medicinal chemistry letters,7(4),397-402. |
MLA | Xu, Heng,et al."Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders".ACS medicinal chemistry letters 7.4(2016):397-402. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论